Systemic Anti Cancer Therapy (SACT) Cancer 52 Ralphael Oghagbon

What is currently available and how do I gain access? Nationally Area Team Hospital Coverage Map Numbers in Treatment Top Regimens Data Completeness Benchmarking Post Chemo Mortality www.chemodataset.nhs.uk

Coverage Map: A National Perspective

So… what do the numbers tell us? February 14 to January ‘15 March 14 to February 15 Patients Receiving Drug Treatments 163,840 165,256 Regimens Commenced 278,354 282,646 Cycles Commenced 774,958 790,868 The figures listed above represent the number of patients reported to the CIU through SACT, for whom treatment activity has been submitted for the period covering August 2013 through July 2014 inclusive.

How good is the data nationally? SACT data completeness, March 2014 to February 2015 Data completeness

How do less common cancers compare to other diagnostic groups

Can I find out how complete my hospital’s Rare Cancer data is? There are reports available to download through the secure online SACT portal: SACT Data Completeness Profile One-page summary by diagnostic group with national comparison SACT Data Quality Profile One-page summary focused on recording of ‘Treatment Intent’ and ‘Cycle Start Date’ data items

Between July 2013 and June 2014, there were 1,709 patients reported to be receiving chemotherapy treatment for haematological malignancies (lymphoma, myeloma, leukaemia).

Top Regimens by Diagnostic Group Brain/CNS ICD10: C47, C69-C72 All submitting trusts aggregated Data received for October 2013 - September 2014. Patients aged 16 and over These reports are available at a provider level There are in excess of 109 regimens for this disease group Total patients recorded as receiving regimen is shown in parenthesis after regimen name e.g. IMATINIB (265) = 3,959 patients receiving IMATINIB. These patients received 1,503 cycles of IMATINIB between July 2013 – June 2014, with 145 being first cycles (starting treatment between July 2013 – June 2014).

Top Regimens by Diagnostic Group Sarcoma ICD10: C40-C41, C46, C49 or various morphology codes All submitting trusts aggregated Data received for October 2013 - September 2014. Patients aged 16 and over These reports are available at a provider level There are in excess of 165 regimens for this disease group Total patients recorded as receiving regimen is shown in parenthesis after regimen name e.g. IMATINIB (265) = 3,959 patients receiving IMATINIB. These patients received 1,503 cycles of IMATINIB between July 2013 – June 2014, with 145 being first cycles (starting treatment between July 2013 – June 2014).

GIST- Gastrointestinal stromal Tumors

Top regimens reported for gastro-intestinal stromal tumours Morphology: M8936 All submitting trusts aggregated Data received for October 2013 - September 2014. Patients aged 16 and over *Curative group includes adjuvant and neo-adjuvant intent

Post Chemotherapy Mortality Analysis From 25th July 2014 all NHS providers of chemotherapy in England have been able to access their 30/60/90-day post chemotherapy mortality analysis through the secure online portal. This analysis is available by tumour group and will provide a national comparison. It is essential that clinical teams within provider organisations check the accuracy of their data and contact the team in Oxford where there are any possible discrepancies. A letter to Medical Directors and Lead Chemotherapy Consultants has been sent out raising awareness of these reports.

Post Chemotherapy Mortality Analysis (2) For demonstration purposes only

Post Chemotherapy Survival Analysis Less Common Cancer all treatment intents For demonstration purposes only Red line = Trust survival curve Blue line = All submitting trusts aggregated (i.e. National average) Quality assurance is vital before post-chemotherapy survival analysis can be released into public domain. Encourage all trusts to actively verify data submitted through SACT.

Cancer Drugs Fund (CDF) data NHS England is responsible for delivery of the Cancer Drugs Fund Public Health England commissioned to audit Cancer Drugs Fund Expectation for Cancer Drugs Fund treatments to be reported through SACT by each hospital

Improving Stakeholder Engagement Members of the CIU team will be attending the following meetings: NHS England Area Team Pharmacist Meeting NHS England Chemotherapy Clinical Reference Group Chemotherapy Clinical Information Group NCIN Site Specific Clinical Reference Groups (SSCRG) e.g. CNS workshop, CTYA meeting Would you like to know more about SACT? Please contact the team, we are always happy to discuss the project or meet with you. E-mail: CIU@phe.gov.uk